Replies to post #12031 on Titan Pharmaceuticals Inc (TTNP)

[Serenity3]

yes an injectable will not be comparable in price to a generic pill, but it should be priced competitively in order to spur adoption of the technology that is more effective and thus will ultimately cost insurance companies less than the current ineffective sublingual or generic pill treatment they pay for.. to whit: 1 ER visit for emergency resuscitation will cost insurance about $30000.. all the medical sequalae that revolve around untreated opioid substance abuse is darn expensive for an insurance company vs the cost of the implant ... is anyone presenting data on this?... still if the price initially is significantly higher than the generic sublingual pill then that is a barrier to quick adoption of the procedure and should be adjusted accordingly